Represents the fair value of asset or liability transfers in a recurring basis between the levels.

No definition available.

Name:	alks_FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevels
Namespace Prefix:	alks_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum milestone payments receivable upon achievement of certain regulatory and sales milestones.

+ References

No definition available.

+ Details

Name:	alks_MaximumMilestonePaymentsReceivableUponAchievementOfCertainRegulatoryAndSalesMilestones
Namespace Prefix:	alks_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment payable.

+ References

No definition available.

+ Details

Name:	alks_MilestonePaymentPayable
Namespace Prefix:	alks_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payment upon regulatory approval of NDA.

+ References

No definition available.

+ Details

Name:	alks_MilestonePaymentUponRegulatoryApprovalOfNonDisclosureAgreement
Namespace Prefix:	alks_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of milestone payments receivable.

+ References

No definition available.

+ Details

Name:	alks_MilestonePaymentsReceivable
Namespace Prefix:	alks_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of equal annual milestone payment upon approval of non disclosure agreement.

+ References

No definition available.

+ Details

Name:	alks_NumberOfEqualAnnualMilestonePaymentUponApprovalOfNonDisclosureAgreement
Namespace Prefix:	alks_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds from milestone payment.

+ References

No definition available.

+ Details

Name:	alks_ProceedsFromMilestonePayment
Namespace Prefix:	alks_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of increase (decrease) in the value of right to a contingent consideration asset.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of asset recognized arising from contingent consideration in a business combination, expected to be realized beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationAssetNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of input used to measure long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258

+ Details

Name:	us-gaap_LongTermDebtMeasurementInput
Namespace Prefix:	us-gaap_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ValuationTechniqueAxis=alks_ValuationTechniqueRealOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=alks_FutureRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=alks_RecroPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Fair Value Measurements - Additional Information (Details)	3 Months Ended
	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($) item Milestone	Mar. 31, 2018 USD ($)	Mar. 31, 2020 item	Dec. 31, 2018 USD ($)
Fair Value
Transfers between the levels		$ 0
Contingent consideration		37,600,000			$ 65,200,000
Increase (decrease) in the fair value of contingent consideration		$ (22,600,000)	$ (1,900,000)
Discount Rate \| Real options approach
Fair Value
Discount rate (as a percent) \| item		15.0
Discount Rate \| Future royalties
Fair Value
Discount rate (as a percent) \| item		16.0
Recro
Fair Value
Milestone payments received		$ 5,000,000.0
Milestone payments receivable upon achievement of certain regulatory and sales milestones		130,000,000.0
Milestone payment upon regulatory approval of New Drug Application		5,000,000.0
Milestone annual payable		$ 45,000,000.0
Number of milestone payment upon approval of New Drug Application \| Milestone		7
Contingent consideration		$ 37,600,000			$ 65,200,000
Increase (decrease) in the fair value of contingent consideration		(22,600,000)	$ (1,900,000)
Recro \| Maximum
Fair Value
Milestone payments receivable		$ 80,000,000.0
Recro \| Forecast
Fair Value
Milestone payments receivable	$ 5,000,000.0
Recro \| Forecast \| Discount Rate
Fair Value
Discount rate (as a percent) \| item				16.0